
|Articles|May 1, 2003
'Exciting Era' Underway
Author(s)Fred Wilson
San Francisco -- Patients with moderate to severe psoriasis can receive efalizumab (Anti-CD11a) continually with no increased toxicity for approximately one year, an ongoing open-label trial shows.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
FDA Accepts Addition of Bemotrizinol as First New Sunscreen Ingredient in 20 Years
2
Dual-Action Microneedle Patch Shows Promise for Psoriasis in Preclinical Study
3
AI Analysis Reveals Menopausal Hair Loss Linked to Systemic Health and Inflammation
4
Novel Botanical Moisturizer Demonstrates Superior Efficacy Over Metronidazole in Phase 2 Rosacea Trial
5














